HopeStage
Back to all studies
RecruitingNCT06132178

Psilocybin followed by accelerated iTBS for treatment-resistant depression

About this titleRead the official source — NCT06132178

This study evaluates the safety and effectiveness of Psilocybin for people with depression.

Medication studyAges 22–65United States
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of Psilocybin for people with depression.

Who could participate?

Listed age limits: 22 years to 65 years.

Listed locations
AustinSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: January 10, 2025
Recruitment status
Recruiting
Enrollment listed in the registry
100
Sponsor
University of Texas at Austin
Sponsor type
University
Study type
Drug
Intervention type
Device, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 22 Years to 65 Years
Official registry ID
NCT06132178
Official title
Show the full official title

Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder

Recruitment & locations

Currently recruiting

Austin

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of Psilocybin for people with depression.

Who is behind this study?

The study sponsor is University of Texas at Austin, a university.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin and Low-dose psilocybin.

Who can participate?

Listed age limits: 22 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies